Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CeriBell, Inc. - Common Stock (NQ:CBLL)

27.36 -0.28 (-1.01%)
Delayed Quote Updated: 9:30 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CeriBell, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indications 
From Ceribell
Via GlobeNewswire
News headline image
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push ↗
CeriBell (NASDAQ:CBLL) outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it... 
Via MarketBeat
News headline image
CeriBell (CBLL) Q2 2026 Earnings Call Transcript ↗
Revenue surged 33% as hospital accounts expanded and delirium reimbursement neared launch. 
Via The Motley Fool
Topics Earnings Intellectual Property World Trade
Ceribell Inc (NASDAQ:CBLL) Q1 Revenue Beats Estimates, Net Loss Widens, Full-Year Guidance Raised ↗
Via Chartmill
Ceribell Inc (NASDAQ:CBLL) Reports Strong Q4 Revenue Beat and Provides 2026 Outlook ↗
Via Chartmill
News headline image
CeriBell Q2 Earnings Call Highlights ↗
CeriBell (NASDAQ:CBLL) reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also... 
Via MarketBeat
Topics Earnings World Trade
News headline image
Ceribell Reports Second Quarter 2026 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
Neurology Review Software Enhancements Included as Part of Industry-Leading Ceribell Point-of-Care Brain Monitoring System 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Medtech Market-Builder Thomas West and Health System Operator Sharon O’Keefe Join Ceribell as Point-of-Care Brain Monitoring Advances Toward Standard of Care 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System... 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
From Ceribell
Via GlobeNewswire
News headline image
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Records ↗
CeriBell (NASDAQ:CBLL) executives said the company’s first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while... 
Via MarketBeat
News headline image
CeriBell Q1 Earnings Call Highlights ↗
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest... 
Via MarketBeat
Topics Earnings
News headline image
CeriBell (CBLL) Q1 2026 Earnings Transcript ↗
CeriBell (CBLL) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics World Trade
News headline image
Ceribell Reports First Quarter 2026 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
From Ceribell
Via GlobeNewswire
News headline image
CeriBell (CBLL) Q4 2025 Earnings Call Transcript ↗
CeriBell (CBLL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Participate in Upcoming March Investor Conferences
From Ceribell
Via GlobeNewswire
News headline image
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the... 
From Ceribell
Via GlobeNewswire
News headline image
AI Diagnostics: The End of the High-Cost Imaging Era
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Ceribell
Via GlobeNewswire
News headline image
Global AI Infrastructure Shift Ignites Biotech Growth Phase
From USA News Group
Via GlobeNewswire
News headline image
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring 
From Ceribell
Via GlobeNewswire
News headline image
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures 
From Ceribell
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.